Nurix Fast Tracked for Treatment of Relapsed or Refractory CLL and SLL

 

Fast track designation follows positive Phase 1 data presented at the American Society of Hematology that supports strategy to broadly develop NX-5948 in CLL and other non-Hodgkin lymphoma indications

https://www.globenewswire.com/news-release/2024/01/16/2810302/0/en/Nurix-Therapeutics-Receives-U-S-FDA-Fast-Track-Designation-for-NX-5948-for-the-Treatment-of-Relapsed-or-Refractory-CLL-and-SLL.html